|Bid||35.14 x 1100|
|Ask||35.15 x 1800|
|Day's range||35.03 - 35.49|
|52-week range||28.47 - 46.97|
|Beta (5Y monthly)||0.29|
|PE ratio (TTM)||13.12|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||1.88 (5.31%)|
|Ex-dividend date||17 Nov 2022|
|1y target est||44.92|
A story of cancer scares, secretive short sellers, psychological tape bombs and post-investment stress disorder
Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.
Wells Fargo, Honeywell International, Northrop Grumman, The Travelers Companies and GSK are included in this Analyst Blog.